Explaining the increase in coronary heart disease mortality in Syria between 1996 and 2006

BMC Public Health

Simon Capewell³  Martin O'Flaherty³  Fouad M Fouad²  Fawaz Mzayek¹  Wasim Maziak⁴  Radwan AL Ali²  Samer Rastam⁵ 

[1] University of Memphis, School of Public Health, Division of Epidemiology and Biostatistics, Memphis, TN, USA;Syrian Centre for Tobacco Studies, Aleppo, Syria;Department of Public Health and Policy, University of Liverpool, Liverpool, UK;Robert Stempel College of Public Health and Social Work, Florida International University, Miami, FL, USA;Syrian Center for Tobacco Studies Syrian Society against Cancer building, St.Aleppo, Shihan, Syria

关键词: Modelling;    Mortality;    Coronary heart disease;   

Others  :  1163137
DOI  :  10.1186/1471-2458-12-754

 received in 2012-01-16, accepted in 2012-08-29,  发布年份 2012

【 摘 要 】

Background

Despite advances made in treating coronary heart disease (CHD), mortality due to CHD in Syria has been increasing for the past two decades. This study aims to assess CHD mortality trends in Syria between 1996 and 2006 and to investigate the main factors associated with them.

Methods

The IMPACT model was used to analyze CHD mortality trends in Syria based on numbers of CHD patients, utilization of specific treatments, trends in major cardiovascular risk factors in apparently healthy persons and CHD patients. Data sources for the IMPACT model included official statistics, published and unpublished surveys, data from neighboring countries, expert opinions, and randomized trials and meta-analyses.

Results

Between 1996 and 2006, CHD mortality rate in Syria increased by 64%, which translates into 6370 excess CHD deaths in 2006 as compared to the number expected had the 1996 baseline rate held constant. Using the IMPACT model, it was estimated that increases in cardiovascular risk factors could explain approximately 5140 (81%) of the CHD deaths, while some 2145 deaths were prevented or postponed by medical and surgical treatments for CHD.

Conclusion

Most of the recent increase in CHD mortality in Syria is attributable to increases in major cardiovascular risk factors. Treatments for CHD were able to prevent about a quarter of excess CHD deaths, despite suboptimal implementation. These findings stress the importance of population-based primary prevention strategies targeting major risk factors for CHD, as well as policies aimed at improving access and adherence to modern treatments of CHD.

【 授权许可】

   
2012 Rastam et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Murray CJ, Lopez AD: Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997, 349(9061):1269-1276.
• [2]World Health Organization: The global burden of disease: 2004 update. 2008.
• [3]World Health Organization: The World health report 2003: shaping the future. WHO, Geneva, Switzerland; 2003.
• [4]Reddy KS: Cardiovascular diseases in the developing countries: dimensions, determinants, dynamics and directions for public health action. Public Health Nutr 2002, 5(1A):231-237.
• [5]Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ: Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006, 367(9524):1747-1757.
• [6]Sarrafzadegan N, Oveisgharan S, Toghianifar N, Hosseini S, Rabiei K: Acute Myocardial Infarction in Isfahan, Iran: Hospitalization and 28th day case-fata;ity Rate. ARYA Atherosclerosis Journal 2009, 5(3):132-137. Fall
• [7]EMRO: Cardiovascular Diseases – prevention and Control – EMRO technical paper Series 7, October. 1998. [ http://www.emro.who.int/dsaf/dsa444.pdf webcite]
• [8]Maziak W, Rastam S, Mzayek F, Ward KD, Eissenberg T, Keil U: Cardiovascular health among adults in Syria: a model from developing countries. Ann Epidemiol 2007, 17(9):713-720.
• [9]Reddy KS, Yusuf S: Emerging epidemic of cardiovascular disease in developing countries. Circulation 1998, 97(6):596-601.
• [10]Gaziano TA: Reducing the growing burden of cardiovascular disease in the developing world. Health Aff (Millwood) 2007, 26(1):13-24.
• [11]World Health Organization: WHO Global Health Observatory. 2004. [ http://apps.who.int/ghodata/ webcite]
• [12]World Health Organization: WHO Statistical Information System. 2006. [ http://www.who.int/whosis/mort/download/en/index.html webcite]
• [13]Capewell S, Beaglehole R, Seddon M, McMurray J: Explanation for the decline in coronary heart disease mortality rates in Auckland, New Zealand, between 1982 and 1993. Circulation 2000, 102(13):1511-1516.
• [14]Critchley J, Liu J, Zhao D, Wei W, Capewell S: Explaining the increase in coronary heart disease mortality in Beijing between 1984 and 1999. Circulation 2004, 110(10):1236-1244.
• [15]Capewell S, Morrison C, McMurray J: Contribution of modern cardiovascular treatment and risk factor changes to the decline in coronary heart disease mortality in Scotland between 1975 and 1994. Heart 1999, 8(4):380-386.
• [16]Central Bureau of Statistics: Central Bureau of Statistics. 2011. [ http://www.cbssyr.org/index-EN.htm webcite]
• [17]United Nations: Department of economics and social affairs. 2011. [ http://www.un.org/esa/population/ webcite]. Accessed on 27 January 2011
• [18]Maziak W, Ward KD, Mzayek F, Rastam S, Bachir ME, Fouad MF, Hammal F, Asfar T, Mock J, Nuwayhid I, et al.: Mapping the health and environmental situation in informal zones in Aleppo, Syria: report from the Aleppo household survey. Int Arch Occup Environ Health 2005, 78(7):547-558.
• [19]Schoen R: The geometric mean of the age-specific death rates as a summary index of mortality. Demography 1970, 7(3):317-324.
• [20]World Health Organization: Noncommunicable diseases. STEPwise surveillance. Syrian Arab Republic Report. 2003. [ http://www.emro.who.int/ncd/pdf/stepwise_syria.pdf webcite]
• [21]Al Ali R, Rastam S, Fouad FM, Mzayek F, Maziak W: Modifiable cardiovascular risk factors among adults in Aleppo, Syria. Int J Public Health 2011, 56(6):653-62.
• [22]Hikita H, Sato A, Nozato T, Kawashima T, Takahashi Y, Kuwahara T, Takahashi A: Low coronary flow velocity and shear stress predict restenosis after sirolimus-eluting stent implantation. Scand Cardiovasc J 2009, 43(5):298-303.
• [23]Horie H, Takahashi M, Minai K, Izumi M, Takaoka A, Nozawa M, Yokohama H, Fujita T, Sakamoto T, Kito O, et al.: Long-term beneficial effect of late reperfusion for acute anterior myocardial infarction with percutaneous transluminal coronary angioplasty. Circulation 1998, 98(22):2377-2382.
• [24]Topol EJ, Califf RM, Vandormael M, Grines CL, George BS, Sanz ML, Wall T, O'Brien M, Schwaiger M, Aguirre FV, et al.: Circulation. 1992, 85(6):2090-2099.
• [25]Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group Lancet 1988, 2(8607):349-360.
• [26]Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group Circulation 1998, 97(22):2202-2212.
• [27]Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 2002, 324((7329):71-86.
• [28]Al-Mallah MH, Tleyjeh IM, Abdel-Latif AA, Weaver WD: Angiotensin-converting enzyme inhibitors in coronary artery disease and preserved left ventricular systolic function: a systematic review and meta-analysis of randomized controlled trials. J Am Coll Cardiol 2006, 47(8):1576-1583.
• [29]Anand SS, Yusuf S: Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. JAMA 1999, 282(21):2058-2067.
• [30]Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, et al.: Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007, 356(15):1503-1516.
• [31]Boersma E, Harrington RA, Moliterno DJ, White H, Theroux P, Van de Werf F, de Torbal A, Armstrong PW, Wallentin LC, Wilcox RG, et al.: Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002, 359(9302):189-198.
• [32]Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, Collins R, Liu LS: Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005, 366(9497):1607-1621.
• [33]Estess JM, Topol EJ: Fibrinolytic treatment for elderly patients with acute myocardial infarction. Heart 2002, 87(4):308-311.
• [34]Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, Torp-Pedersen C, Ball S, Pogue J, Moye L, et al.: Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000, 355(9215):1575-1581.
• [35]Fox KA, Poole-Wilson P, Clayton TC, Henderson RA, Shaw TR, Wheatley DJ, Knight R, Pocock SJ: 5-year outcome of an interventional strategy in non-ST-elevation acute coronary syndrome: the British Heart Foundation RITA 3 randomised trial. Lancet 2005, 366(9489):914-920.
• [36]Freemantle N, Cleland J, Young P, Mason J, Harrison J: beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999, 318(7200):1730-1737.
• [37]Hulten E, Jackson JL, Douglas K, George S, Villines TC: The effect of early, intensive statin therapy on acute coronary syndrome: a meta-analysis of randomized controlled trials. Arch Intern Med 2006, 166(17):1814-1821.
• [38]Keeley EC, Boura JA, Grines CL: Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003, 361(9351):13-20.
• [39]Kjekshus J, Apetrei E, Barrios V, Bohm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, et al.: Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007, 357(22):2248-2261.
• [40]Law M, Wald N, Morris J: Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy. Health Technol Assess 2003, 7(31):1-94.
• [41]Nadkarni VM, Larkin GL, Peberdy MA, Carey SM, Kaye W, Mancini ME, Nichol G, Lane-Truitt T, Potts J, Ornato JP, et al.: First documented rhythm and clinical outcome from in-hospital cardiac arrest among children and adults. JAMA 2006, 295(1):50-57.
• [42]Oler A, Whooley MA, Oler J, Grady D: Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA 1996, 276(10):811-815.
• [43]Pignone M, Phillips C, Mulrow C: Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials. BMJ 2000, 321(7267):983-986.
• [44]Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341(10):709-717.
• [45]Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P, Claeys MJ, Cools F, Hill KA, Skene AM, et al.: Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005, 352(12):1179-1189.
• [46]Shibata MC, Flather MD, Wang D: Systematic review of the impact of beta blockers on mortality and hospital admissions in heart failure. Eur J Heart Fail 2001, 3(3):351-357.
• [47]Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G: Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372(9645):1231-1239.
• [48]Taylor RS, Brown A, Ebrahim S, Jolliffe J, Noorani H, Rees K, Skidmore B, Stone JA, Thompson DR, Oldridge N: Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med 2004, 116(10):682-692.
• [49]Tunstall-Pedoe H, Bailey L, Chamberlain DA, Marsden AK, Ward ME, Zideman DA: Survey of 3765 cardiopulmonary resuscitations in British hospitals (the BRESUS Study): methods and overall results. BMJ 1992, 304(6838):1347-1351.
• [50]Wilt TJ, Bloomfield HE, MacDonald R, Nelson D, Rutks I, Ho M, Larsen G, McCall A, Pineros S, Sales A: Effectiveness of statin therapy in adults with coronary heart disease. Arch Intern Med 2004, 164(13):1427-1436.
• [51]Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001, 345(7):494-502.
• [52]Yusuf S, Zucker D, Peduzzi P, Fisher LD, Takaro T, Kennedy JW, Davis K, Killip T, Passamani E, Norris R, et al.: Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 1994, 344(8922):563-570.
• [53]IMPACT Model: IMPACT Model Appendices. 2007. [ http://www.liv.ac.uk/PublicHealth/sc/bua/IMPACT_Model_%20Appendices_May_2007.pdf webcite]
• [54]MacIntyre K, Capewell S, Stewart S, Chalmers JW, Boyd J, Finlayson A, Redpath A, Pell JP, McMurray JJ: Evidence of improving prognosis in heart failure: trends in case fatality in 66 547 patients hospitalized between 1986 and 1995. Circulation 2000, 102(10):1126-1131.
• [55]Critchley JA, Capewell S: Substantial potential for reductions in coronary heart disease mortality in the UK through changes in risk factor levels. J Epidemiol Community Health 2003, 57(4):243-247.
• [56]Critchley JA, Capewell S, Unal B: Life-years gained from coronary heart disease mortality reduction in Scotland: prevention or treatment? J Clin Epidemiol 2003, 56(6):583-590.
• [57]Butler J, Arbogast PG, BeLue R, Daugherty J, Jain MK, Ray WA, Griffin MR: Outpatient adherence to beta-blocker therapy after acute myocardial infarction. J Am Coll Cardiol 2002, 40(9):1589-1595.
• [58]Briggs A, Sculpher M, Buxton M: Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Econ 1994, 3(2):95-104.
• [59]Gupta R: Burden of coronary heart disease in India. Indian Heart J 2005, 57(6):632-638.
• [60]Musaiger AO: Overweight and obesity in eastern mediterranean region: prevalence and possible causes. J Obes 2011, 2011:407237.
• [61]State Planning commission of Syrian Arab Republic: The Tenth Five Years Planning 2006–2010. Chapet 20: Heath. 2006.
• [62]Albache N, Al Ali R, Rastam S, Fouad FM, Mzayek F, Maziak W: Epidemiology of Type 2 diabetes mellitus in Aleppo, Syria. J Diabetes 2010, 2(2):85-91.
• [63]Unal B, Critchley JA, Capewell S: Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2000. Circulation 2004, 109(9):1101-1107.
• [64]Beaglehole R, Bonita R, Alleyne G, Horton R: NCDs: celebrating success, moving forward. Lancet 2011, 378(9799):1283-1284.